Edesa Biotech EBITDA
Was ist das EBITDA von Edesa Biotech?
EBITDA von Edesa Biotech, Inc. ist -$20.91
Was ist die Definition von EBITDA?
Das EBITDA ist das Ergebnis eines Unternehmens vor Zinsen, Steuern, Abschreibungen und Amortisationen und ist eine Buchhaltungsgröße, die anhand des Nettoergebnisses eines Unternehmens berechnet wird, bevor Zinsaufwendungen, Steuern, Abschreibungen und Amortisationen abgezogen werden, um die derzeitige operative Ertragskraft eines Unternehmens zu ermitteln.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Edesa Biotech
Was macht Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Unternehmen mit ebitda ähnlich Edesa Biotech
- Sensorion SAS hat EBITDA von -€21.02
- Lifeist Wellness hat EBITDA von -CAD$21.01
- Zagg Inc hat EBITDA von -$20.98
- Tree House Education & Accessories hat EBITDA von -₨20.95
- China International Development hat EBITDA von -HKD$20.94
- Nexus Minerals hat EBITDA von -AUD$20.93
- Edesa Biotech hat EBITDA von -$20.91
- Invinity Systems hat EBITDA von -£20.91
- Novatti hat EBITDA von -AUD$20.90
- Mohawk hat EBITDA von -$20.89
- Asia Pioneer Entertainment hat EBITDA von -HKD$20.88
- Mednow hat EBITDA von -CAD$20.87
- Mednow hat EBITDA von -CAD$20.87